Sponsored content brought to you by
IRBM is an innovative contract research organization (CRO) that works across all aspects of drug discovery and early development. It fosters collaborations with pharmaceutical and biotech companies, investors, as well as nonprofit and academic sectors to accelerate drug discovery—from target identification through to candidate nomination and providing scientific and commercial validation.
Integrated drug discovery across many modalities
A spin-out with global pharma heritage from Merck & Co., IRBM’s “drug hunters” apply decades of experience to identify the most promising clinical candidates, based on best-in-class processes. Its success is exemplified by four key therapeutics on the market where it has played a pivotal role. IRBM covers multiple research areas including oncology, infectious diseases, neuroscience, as well as rare and neglected diseases.
Offering expertise in multiple modalities, including small molecules, peptides, and antibodies, IRBM’s team of multidisciplinary scientists are based at its state-of-the-art R&D facility near Rome, Italy.
Integrate IRBM’s drug discovery engine into your development pipeline
IRBM’s experienced scientists validate targets, identify hits, and progress them through tailor-made, constantly evolving screening cascades. Its diverse screening libraries ensure that the best candidate is selected for a wide range of targets and modalities.
IRBM’s target validation team can employ several platform technologies to demonstrate disease relevance of targets and elucidate druggable attributes. This can be done in conjunction with IRBM’s biomarker identification & development capabilities. After hit identification, expansion, and screening, IRBM’s experienced in-house chemists select the most attractive hits and hit series for development to leads. The most promising leads are then extensively optimized for biological activity and drug-like properties using a broad suite of assays and screens.
To date, IRBM has identified and helped support IND applications for over 25 clinical candidates (including two peptides)—ensuring that only the most promising, high-quality candidates progress to clinical development.
Peptide and antibody drug discovery
As a leading expert in the field of peptide therapeutic drug discovery, IRBM’s experience covers the entire process, from the synthesis of putative peptide leads to delivering a suitable candidate. With 20 years’ expertise in phage display, we can use our in-house peptide libraries or build custom libraries to find the best peptide hits.
IRBM’s phage display antibody library has >50 billion unique fully human antibodies, with diversity and design that delivers therapeutic leads against all types of antigens, including difficult targets.
De-risk in-licensing with world-class candidate and data validation
IRBM is dedicated to delivering innovation and adding value at the vital intersection of industry and academic research. When seeking drugs to in-license, IRBM ‘s expertise and pharma heritage helps provide external validation on the drug discovery science and data behind potential candidates. Its technical and commercial validation can therefore help to de-risk candidate in-licensing and investment.
At any phase of drug discovery and early development, IRBM achieves excellence through partnership, delivering above expectations. We are driven by a passion for science—helping to develop innovative and effective clinical therapies that could ultimately improve patients’ quality of life.
“At IRBM, we’re motivated by complex projects, difficult targets, and molecules that require solutions-focused innovation. Our world-class team has a can-do, relentless approach to overcoming challenges, founded on integrity and paired with an impressive suite of capabilities under one roof, which consistently delivers value to our partners.” —Carlo Toniatti, MD, PhD, CSO, IRBM